Angiotensin II type 1 receptor (AT1R) mediates the cardiovascular actions of angiotensin II. Growing studies have revealed the underlying association between AT1R-A1166C (rs5186) polymorphism and coronary heart disease (CHD) among the East Asia population. Results from these studies remain conflicting. We conducted this meta-analysis to estimate the overall CHD risk of AT1R-A1166C polymorphism regarding the East Asia population. We searched the PubMed, Embase and China National Knowledge Infrastructure (CNKI) databases for all articles within a range of published years from 1995 to 2011. The odds ratio (OR) corresponding to the 95% confidence interval (CI) was used to assess the different associations. The statistical heterogeneity among studies was assessed with the Q-test and I 2 statistics. Up to December 2011, 17 case-control studies, including 2,366 cases and 2,414 controls, were available for our study. The C allele and the AC/CC genotypes were associated with significantly increased risk of CHD (OR = 1.59, 95% CI = 1.22-2.06 for C versus A and OR = 1.57, 95% CI = 1.16-2.13 for AC/CC versus AA, respectively). Our result suggested that AT1R-A1166C polymorphism may be involved in the development of CHD.
Introduction
Coronary heart disease (CHD) remains a leading cause of death and disability worldwide. 1, 2 A recent report from the American Heart Association showed that approximately every 25 seconds, an American will have a coronary event, and approximately every minute, someone will die of one. 3 The development of CHD is the result of genetic and environmental interaction. Several risk factors for CHD, including hypercholesterolemia, hypertension, smoking and diabetes mellitus have been identified by epidemiological studies. However, there are many other candidate risk factors, one of which is gene polymorphism of the renninangiotensin system (RAS).
Angiotensin II type 1 receptor (AT1R) is a G proteincoupled receptor that mediates most of the biological actions of the RAS. Classically, the angiotensin II receptor includes two subtypes: type 1 receptor and type 2 receptor. 4 The AT1R gene is located on the long arm of chromosome 3 (3q21-25), composed of five exons and four introns. A1166C variant (rs5186) is located in the 3' untranslated region, in which there is an A to C transversion. The association of this variant with cardiovascular diseases has been revealed, but the results are conflicting.
Meta-analysis suggested that AT1R-A1166C polymorphism was associated with susceptibility to hypertension, 5, 6 but not ischemic stroke. 7 To date, a number of molecular epidemiological studies have been done to evaluate the association between this variant and CHD risk, but the results are still conflicting. Several studies [8] [9] [10] [11] [12] [13] [14] [15] [16] found that the C allele in AT1R-A1166C was a risk factor for CHD, but other researchers [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] found a contrasting result.
Considering that a single study might have been underpowered to detect the overall effects that a single mutation can have on populations with different genetic backgrounds, a quantitative synthesis of the accumulated data from different studies was deemed important to provide evidence of the association of this variant with CHD risk. So, we carried out this meta-analysis on all published casecontrol studies to estimate the overall CHD risk of AT1R-A1166C polymorphism in the East Asia area, to quantify heterogeneity between the individual studies as well as to investigate the existence of potential publication bias.
Materials and methods

Publication search and inclusion criteria
We searched the PubMed, Embase and China National Knowledge Infrastructure (CNKI) databases for all articles within a range of published years from 1995 to 2011 on the association between AT1R-A1166C polymorphism and CHD risk (last search was updated 30 December 2011). The following terms were used in this search: 'angiotensin II type-1 receptor' and 'coronary heart disease or myocardial infarction' and 'polymorphism or polymorphisms.' In order to identify the relevant publications, the references cited in the research papers were also scanned.
Studies testing the association between AT1R-A1166C polymorphism and CHD risk were included if all the following conditions were met: (a) the publication was a case-control study; (b) an evaluation of the association of AT1R-A1166C polymorphism and CHD was included; (c) the CHD diagnosis complied with the diagnosis criteria of the World Health Organization (WHO); (d) the study authors reported odds ratio (OR) data for their calculation; (e) the control subjects satisfied the Hardy-Weinberg equilibrium (HWE); and (f) the study was published in English or Chinese.
Data extraction
Data from these studies were extracted by Kui Zhang and Bin Zhou. Publications were read by Kui Zhang in order to check original data extraction. If the studies had the same or overlapping data, [30] [31] [32] [33] [34] [35] [36] we selected the more recent one with a larger number of participants. Finally, the data for this meta-analysis were available from 17 case-control studies, including 2,366 cases and 2,414 controls. The following information was recorded for each study: first author, year of publication, region, number of alleles, number of genotypes, genotyping methods, matching criteria, frequencies of C allele in control subjects and evidence of HWE in control subjects (all of the data are shown in Table 1 ).
Statistical analysis
The OR corresponding to the 95% confidence interval (CI) was used to assess the association between AT1R-A1166C polymorphism and risk of CHD. We evaluated the risk of the C allele on CHD compared with the A allele and then calculated the OR of AC/CC genotypes versus AA genotype using the dominant genetic model of the C allele.
The statistical heterogeneity among studies was assessed with the Q-test and I 2 statistics. 37 If there was no obvious heterogeneity, the fixed-effects model (the Mantel-Haenszel method) was used to estimate the summary OR; 38 otherwise, the random-effects model (the DerSimonian and Laird method) was used. 39 To explore sources of heterogeneity across studies, we did logistic meta-regression analyses. We examined the following study characteristics: publication year, region, genotyping, matching criteria, number of alleles and number of genotypes. The HWE was assessed by Fisher's exact test (significance set at p<0.10). Publication bias was evaluated with funnel plot and Begg's rank correlation method. 40 The statistical analyses were performed by STATA 12.0 software (Stata Corp., College Station, TX).
Results
Characteristics of studies
Overall, 17 case-control studies with 2,366 cases and 2,414 controls were available for this analysis. Among the above studies, two studies with 105 cases and 174 controls were available for diabetes sub-analysis, and four studies with 427 cases and 513 controls were available for hypertension sub-analysis. Study characteristics are summarized in Table 1 . The sample size in these case-control studies varied considerably (ranging from 116 to 920 individuals). Two genotyping methods were used, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and polymerase chain reaction-allele specific oligonucleotide (ASO-PCR). The genotype distributions among the controls of all studies were consistent with HWE, and those disagreeing with HWE were intentionally excluded from our research. 41 
Quantitative synthesis
For control subjects, C allele frequency of AT1R-A1166C polymorphism ranged from 0.020 to 0.225. The evaluation of the association of AT1R-A1166C polymorphism with CHD risk is shown in Figure 1 and Figure 2 .
The C allele and the AC/CC genotypes were associated with a significantly increased risk of CHD (OR = 1.59, 95% CI = 1.22-2.06 for C versus A and OR = 1.57, 95% CI = 1.16-2.13 for AC/CC versus AA, respectively) by a random effects model. After stratified analyses, the patients who had diabetes mellitus with C allele of AT1R-A1166C polymorphism were more susceptible to CHD (OR = 3.99, 95% CI = 1.78-8.97 for C versus A and OR = 4.08, 95% CI = 1.76-9.45 for AC/CC versus AA, respectively). However, no significantly elevated risk with CHD was found in the patients with hypertension (OR = 1.22, 95% CI = 0.57-2.63 for C versus A and OR = 1.02, 95% CI = 0.47-2.25 for AC/ CC versus AA, respectively).
Evaluation of heterogeneity
There was heterogeneity among studies in overall comparisons (P heterogeneity = 0.001, I 2 = 59.2%, Tau 2 = 0.1516 for C versus A and P heterogeneity = 0.000, I 2 = 63.6%, Tau 2 = 0.2238 for AC/CC versus AA, respectively). To explore sources of heterogeneity across studies, we assessed allele comparison (C versus A) and dominant model comparison (AC/CC versus AA) by source of publication year, region, genotyping methods, matching criteria, quantity of C allele in the CHD group, quantity of A allele in the CHD group, quantity of C allele in the control group, quantity of A allele in the control group, quantity of AC/CC genotypes in the CHD group, quantity of AA genotype in the CHD group, quantity of AC/ CC genotypes in the control group and quantity of AA genotype in the control group. We found that quantity of C allele in the CHD group (P = 0.002 for allele comparison), quantity of C allele in the control group (P = 0.006 for allele comparison), quantity of A allele in the control group (P = 0.018 for allele comparison), quantity of AC/CC genotypes in the CHD group (P = 0.001 for dominant genetic model comparison), quantity of AC/CC genotypes in the control group (P = 0.006 for dominant genetic model comparison), but not publication year, region, genotyping methods or matching criteria (P > 0.05) could substantially influence the initial heterogeneity.
Sensitivity analysis
The influence of a single study on the overall meta-analysis estimate was investigated by omitting one study at a time, and the omission of any study made no significant difference, indicating that our results were statistically reliable.
Publication bias
Begg's test was performed to evaluate the publication bias of selected literatures. Figure 3 displays a funnel plot that examined the AT1R-A1166C polymorphism and overall CHD risk included in the meta-analysis.
No evidence of publication bias in our study was observed (P = 0.763).
Discussion
In this study, we performed a systematic review of the association between AT1R-A1166C polymorphism and risk for CHD based on 17 case-control studies for which information was available. Our meta-analysis identified that the C allele and AC/CC genotypes had a statistically significant increased CHD risk in East Asia by a random effects model. These findings indicated that AT1R-A1166C polymorphism may play a role in CHD development.
AT1R mediates the cardiovascular actions of angiotensin II [42] [43] [44] and is a member of the G-protein-coupled receptor superfamily expressed in most tissues, where receptor activation leads to vasoconstriction, water retention and vascular smooth muscle cell proliferation and hypertrophy. 45, 46 It can still stimulate reactive oxygen species within the cell nucleus. 47 Functional studies indicate that the expression of the A allele, rather than C allele, was down regulated by miR-155. Further evidence from rodent models shows that the C allele regulated the expression of the AT1R gene by weakening the ability of miR-155. 48 That may be the possible mechanism of AT1R-A1166C polymorphism involvement in the development of CHD, but further studies are needed to confirm the potential mechanism. Previous meta-analysis conducted by Zhang suggests that the C allele of AT1R-A1166C polymorphism is associated with an increased risk of myocardial infarction (MI). 49 Xu et al. conducted a meta-analysis, and their results suggest that AT1R-A1166C polymorphism was associated with increased CHD risk in the overall analysis. However, null result was found in the East Asia population in an analysis by geographic region. 50 Our result suggests that AT1R-A1166C polymorphism may have a statistically significant increased CHD risk. Due to the relatively small size of studies available, further studies with larger participants are needed to confirm this result.
Stratified analyses were performed to reveal the association of CHD risk with AT1R-A1166C polymorphism in CHD patients with diabetes or hypertension. The patients who had diabetes mellitus with C allele of AT1R-A1166C polymorphism were more susceptible to CHD. Nevertheless, no significantly elevated risk with CHD was found in the patients with hypertension. The null result may be due to the limited number of studies, with only four studies available in this meta-analysis.
Our study evaluated the heterogeneity, and the results included the heterogeneity for C versus A (P heterogeneity = 0.001, I 2 = 59.2%, Tau 2 = 0.1516) and for AC/CC versus AA (P heterogeneity = 0.000, I 2 = 63.6%, Tau 2 = 0.2238). However, meta-regression analyses with the dependent variable logarithm OR found the heterogeneity was not related to the publication year, region, genotyping methods or matching criteria (P > 0.05), but related to quantity of C allele in the CHD group (P = 0.002 for allele comparison), quantity of C allele in the control group (P = 0.006 for allele comparison), quantity of A allele in the control group (P = 0.018 for allele comparison), quantity of AC/CC genotypes in the CHD group (P = 0.001 for dominant genetic model comparison) and quantity of AC/CC genotypes in the control group (P = 0.006 for dominant genetic model comparison). Because only 17 case-control studies with 2,366 cases and 2,414 controls were thus far available for this analysis, further studies using large numbers of participants should be conducted to validate the association. There was no strong evidence that any single factor played an important role in explaining the heterogeneity observed. The influence of a single study on the overall meta-analysis estimate was investigated by omitting one study at a time, and the omission of any study made no significant difference, indicating that our results were statistically reliable. The Begg's test denied the publication bias in our study (P = 0.763).
The data included in the present meta-analysis have some limitations: (a) all enrolled studies were case-control studies, in which cases were survivors of cardiovascular events, and those who did not survive were not included; (b) to date, only 17 studies were available for this study; the relatively small size of participants was responsible for the heterogeneity; (c) this study was conducted relating to an East Asia population, and the populations of other races were underrepresented; (d) most of the enrolled studies only included the association of AT1R-A1166C polymorphism with CHD; further studies estimating the effect of gene-gene and gene-environment interactions may eventually provide a better, comprehensive understanding; and (e) due to the low frequency of the minor allele, analysis by using any more genetic models is difficult.
In conclusion, this meta-analysis indicated that AT1R-A1166C polymorphism was involved in the development of CHD. However, well-designed studies with a larger sample size should be conducted to confirm this result. Moreover, further studies estimating the effect of genegene and gene-environment interactions may eventually provide a better, comprehensive understanding.
